drugset / Trial / NCT00367471
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the optimally-tolerated regimens (OTR) for lapatinib in combination with paclitaxel, carboplatin with and without trastuzumab in patients with metastatic breast cancer.
Timeline
- Start
- 2006-12-07
- Primary completion
- 2010-12-22
- Completion
- 2019-09-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lapatinib | Small molecule | — | Oral |
| Comparator | Trastuzumab | Monoclonal antibody | — | Intravenous |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Paclitaxel | Small molecule | — | Intravenous |